Our finding that this remains possible independent of CFTR activity or expression has potentially important implications for patients with CF, who may benefit from linaclotide’s bicarbonate-stimulatory effect, in addition to its inhibitory effect on NHE3, even if they cannot leverage its pro-chloride secretory properties (6). Here, SLC9A3 is linked to cystic fibrosis.